Comparative pharmacoeconomic study of vancomycin and teicoplanin in intensive care patients

International Journal of Antimicrobial Agents

Volumn 15, Issue 1, 2000, Pages 65-71

  Abad, Francisco ^a   Calbo, Francisco ^b   Zapater, Pedro ^c   Rodríguez Vilanova, Francisco ^b   García Pérez, Luis Emilio ^d   Sacristán, José A ^d  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^c MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^d DCRandT   (Spain)

Author keywords

Intensive care patients; Teicoplanin; Vancomycin

Indexed keywords

TEICOPLANIN; VANCOMYCIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BACTERIAL INFECTION; COST CONTROL; COST MINIMIZATION ANALYSIS; COST OF ILLNESS; DRUG COST; FEMALE; HEALTH CARE COST; HUMAN; INTENSIVE CARE; MALE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; DISEASE; DRUG COSTS; DRUG THERAPY; FEMALE; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TEICOPLANIN; VANCOMYCIN;

EID: 0034040513     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(00)00123-0     Document Type: Article

References (18)

1. Cobo J. Vancomicina y teicoplanina: aspectos diferenciales. Enfer. Infecc. Microbiol. Clin. 13:1995;600-610.
2. Wood Mj. The comparative efficacy and safety of teicoplanin and vancomycin. J. Antimicrob. Chemother. 37:1996;209-222.
3. Zeckel M.L. A closer look at vancomycin, teicoplanin, and antimicrobial resistance. J. Chemother. 9:1997;311-335.
4. Sacristán JA. Farmacoeconomía aplicada a la terapéutica con antimicrobianos. IV Congreso de la Sociedad Española de Quimioterapia. Bilbao, Oct 28-30, 1996.
5. Abad Santos F., Martínez Sancho E., Fernández Muñoz J., Galicia de Pedro I. Farmacoeconomía del tratamiento con antibióticos. Farmacoterapia. 14:1997;295-304.
6. Honorato J., López de Ocariz A., Díaz M. Farmacoeconomía y antibióticos. Actualidades Infección Grampositivos. 5:1995;1-7.
7. Abad Santos F, Fernández Muñoz J. Farmacoeconomía en antibioterapia. X Curso de Avances en Antibioterapia. Servicio de Microbiología, Hospital Universitario de la Princesa, Madrid, 1997.
8. Menichetti F., Martino P., Bucaneve G. et al. Effects of teicoplanin and those of vancomycin in initial empirical antibiotic regimen in febrile, neutropenic patients with haematological malignancies. Antimicrob. Agents Chemother. 38:1994;2041-2046.
9. Wilson A.P.R., Gruneberg R.N., Neu H. A critical review of the dosage of teicoplanin in Europe and the USA. Int. J. Antimicrob. Agents. 4(suppl. 1):1994;S1-S30.
10. Figuera A., Tomas J.F., Hernández L. et al. Imipenem combinado con teicoplanina o vancomicina en el tratamiento empírico inicial de la neutropenia febril: análisis de la respuesta primaria y de una estrategia secuencial global en 126 episodios. Rev. Clin. Esp. 196:1996;515-522.
11. Garrelts J.C., Horst W.D., Silkey B., Gagnon S. A pharmacoeconomic model to evaluate antibiotic costs. Pharmacotherapy. 14:1994;438-445.
12. Spencer C.M., Bryson H.M. Teicoplanin: a pharmacoeconomic evaluation of its use in the treatment of gram-positive infections. PharmacoEconomics. 7:1995;357-374.
13. Crane V.S., Garabedian-Ruffalo S.M. Current treatment of gram positive infections: focus on efficacy, safety and cost minimization analysis of teicoplanin. Hosp. Formul. 27:1992;1199-1210.
14. Cantú T.G., Yamanaka-Yuen N.A., Lietman P.S. Serum vancomycin concentrations: reappraisal of their clinical value. Clin. Infect. Dis. 18:1994;533-543.
15. Moellering R.C. Monitoring serum vancomycin levels: climbing the mountain because it is there? Clin. Infect. Dis. 18:1994;544-546.
16. Vazquez L., Pérez-Encinas M., Santos Morín L., Vilches P., Gutierrez N., García-Sanz R. et al. Randomized prospective study comparing cost-effectiveness of teicoplanin and vancomycin as second-line empiric therapy for infection in neutropenic patients. Haematologica. 84:1999;231-236.
17. Oparaoji E.C., Siram S., Anosike R., Pippalla R.S., Mezghebe H.M. Cost benefit analysis of monitoring serum vancomycin concentrations in a teaching hospital. J. Clin. Pharm. 10:1997;122-126.
18. Davey P.G., South R., Malek M. Impact of glycopeptide therapy after hospital discharge on inpatient costs: a comparison of teicoplanin and vancomycin. J. Antimicrob. Chemother. 37:1996;623-633.